Effectiveness of GLP-1 Receptor Agonists in T2DM and Obesity
BMJ Open
Summary
This retrospective cohort study evaluates the impact of GLP-1 receptor agonists on BMI and blood glucose levels in patients with T2DM and obesity. Using difference-in-difference analysis, it compares GLP-1RA with other second-line antidiabetic treatments over a 24-month period. Findings indicate significant BMI reduction and improved glycaemic control in the GLP-1RA group, suggesting its preference for obese T2DM patients not responsive to metformin monotherapy.
Study Design
Interventions
Study Type
Outcomes
Duration and Size
Study Population
Age Range
Sex
Geography
Other Criteria
Methodology
Data were collected retrospectively from patients receiving GLP-1RA or other second-line treatments. Analysis used linear mixed-effect regression with inverse probability weighting to adjust for confounders.
Interventions
Interventions included GLP-1RAs such as exenatide, liraglutide, and semaglutide administered over 24 months.
Key Findings
GLP-1RA treatments led to greater reductions in BMI and blood glucose compared with other therapies, supporting their use for T2DM with obesity.
Comparison with other Studies
The findings align with previous RCTs and observational studies indicating sustained BMI and glucose improvements with GLP-1RA.
Journal Reference
Siriyotha S, Anothaisintawee T, Looareesuwan P, et al. Effectiveness of GLP-1 receptor agonists for reduction of BMI and blood glucose in T2DM. BMJ Open. 2024;14:e086424. doi:10.1136/bmjopen-2024-086424.
Related and Discussions
Navigating GLP-1 Agonists: A Comprehensive Journey Through Past, Present, and Future Perspectives
The Future of GLP-1 Receptor Agonists: A Precision Medicine Approach
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists in Obesity Management
Comparative Effectiveness of GLP-1 Receptor Agonists on Glycaemic Control and Weight Loss in Type 2 Diabetes
Efficacy and Safety of GLP-1 Receptor Agonists Versus SGLT-2 Inhibitors in Overweight or Obese Patients
The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Overweight and Obese Patients
Systematic Review and Meta-Analysis for Prevention of Major Adverse Cardiac Events with GLP-1 Receptor Agonists
Potential impact of GLP-1 receptor agonists on global mortality linked to obesity and type 2 diabetes
Preliminary studies suggest GLP-1 receptor agonists may have psychiatric benefits
Stay informed. Stay ahead.
Subscribe now for the latest breakthroughs, expert insights, and cutting-edge updates in diabetes care—delivered straight to your inbox.